SCHEMBL7762271

SCHEMBL7762271

O=C(c1ccccc1)N1CCC(C2CN(C(=O)c3ccc(Br)cc3)C2)CC1

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
HPGD P15428 1/20 0.55
ACHE P22303 1/20 0.55
CHRNB2 P17787 1/20 0.54
CHRNB4 P30926 1/20 0.54
CHRNA3 P32297 1/20 0.54
CHRNA7 P36544 1/20 0.54
CHRNA4 P43681 1/20 0.54
KMT2A Q03164 3/20 0.53
MGLL Q99685 2/20 0.52
HSD11B1 P28845 2/20 0.52
EPHX1 P07099 1/20 0.51
GPR183 P32249 1/20 0.51
LMNA P02545 1/20 0.50
TP53 P04637 1/20 0.50
UBE2M P61081 1/20 0.50
DCUN1D1 Q96GG9 1/20 0.50
MEN1 O00255 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7768050 0.83 MGLL (0.57) L3MBTL3L3MBTL1ACHECHRNB2CHRNB4
SCHEMBL693149 0.80 L3MBTL3 (0.59) L3MBTL3L3MBTL1HPGDKMT2AMGLL
SCHEMBL13801428 0.77 SIGMAR1 (0.72) L3MBTL3L3MBTL1HPGDACHECHRNB2
SCHEMBL4465735 0.77 RAB9A (0.75) L3MBTL3L3MBTL1HPGDHSD11B1LMNA
SCHEMBL15949361 0.77 L3MBTL3 (0.56) L3MBTL3L3MBTL1HPGDKMT2AMGLL
SCHEMBL5880849 0.77 HPGD (0.68) L3MBTL3L3MBTL1HPGDKMT2AMGLL
SCHEMBL6580374 0.75 ACHE (0.69) L3MBTL3L3MBTL1HPGDACHEKMT2A
SCHEMBL8988831 0.75 ACHE (0.69) L3MBTL3L3MBTL1HPGDACHEKMT2A
SCHEMBL14676930 0.74 CHRNB2 (0.71) L3MBTL3L3MBTL1HPGDACHECHRNB2
SCHEMBL4003983 0.74 ACHE (0.73) L3MBTL3L3MBTL1HPGDACHEKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100324012-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-12-23 US disclosed
US-20100324012-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-12-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324012-A1 AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS PNLIP, LPL, LIPA L3MBTL3 2111/4885L3MBTL1 1011/4885HPGD 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.